Tysabri Crohn’s Disease Market Assessment
A Panel Discussion among Ten Gastroenterologists
Price: $2500
Deliverable: Transcript with key findings.
Study Description and Objectives
To conduct a panel discussion among gastroenterologists to assess the current and future market for Tysabri® (natalizumab) in Crohn’s disease patients. Secondary objectives:
§ Understand current usage patterns for Tysabri, including patient types and lines of therapy
§ Determine patient demand
§ Uncover drivers and barriers for prescribing
§ Gauge expected levels of future prescribing
§ Examine PML risk and the impact any future PML cases would have on use
§ Identify other factors that will impact the Tysabri market, including products in the pipeline
Companies and Products Mentioned in This Report
|
Company |
Ticker Symbol |
Product(s) |
|
Biogen Idec and Élan Corporation |
BIIB, ELN |
Tysabri® |
|
Centocor, Inc. wholly owned subsidiary of Johnson & Johnson |
JNJ |
Remicade® |
|
Abbott |
ABT |
Humira® |
|
Nektar and UCB Pharma |
NKTR |
Cimzia® |
|
GlaxoSmithKline |
GSK |
Imuran® |
Inclusion Criteria and Panel Details
|
Inclusion Criteria |
§ US-based § Training and board-certification in gastroenterology § 2 to 30 years of experience post-training § From academic and community-based medical centers § Personally treat a high volume of Crohn’s disease patients § Prescribe Tysabri |
|
Discussion Dates |
June 20, 2008 through June 30, 2008. |
To purchase this report or request additional information, contact:
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Other |